Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

By S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena, A. Bardelli. Cancer Research, 2007

813 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EGFR antagonists in cancer treatment. (2008, methodology): “by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).(1-10) Details of the BCBSA TEC assess-”
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. (2009, methodology): “Two broad findings emerged from the TEC assessment of these studies: (1) a consistent correlation between presence of a KRAS mutation in codon 12 or 13 and lack of response to anti-EGFR MoAb therapy in patients with metastatic colorectal cancer; and (2) evidence of improved tumor response, progressi”
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, methodology): “KRAS mutation analysis was performed by direct sequencing as described previously.(6-8) All patients in the Leuven and Italian datasetsprovidedwritten informedconsenttotheoriginalclinicaltrialandtomolecular analyses.”
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (2008, background): “Lastly, there has been a report on two KRAS mutant patients with an OR on CTX [9, 10].”